| Geld/Brief | 29,00 $ / 29,47 $ |
| Spread | +1,62% |
| Schluss Vortag | 29,51 $ |
| Gehandelte Stücke | 21.765 |
| Tagesvolumen Vortag | 94.134,04 $ |
| Tagestief 28,27 $ Tageshoch 29,33 $ | |
| 52W-Tief 9,97 $ 52W-Hoch 34,24 $ | |
| Jahrestief 27,24 $ Jahreshoch 34,24 $ | |
| Umsatz in Mio. | 0,30 $ |
| Operatives Ergebnis (EBIT) in Mio. | -299,04 $ |
| Jahresüberschuss in Mio. | -269,95 $ |
| Umsatz je Aktie | - |
| Gewinn je Aktie | -3,37 $ |
| Gewinnrendite | -40,19% |
| Umsatzrendite | - |
| Return on Investment | -36,36% |
| Marktkapitalisierung in Mio. | 1.535 $ |
| KGV (Kurs/Gewinn) | -5,69 |
| KBV (Kurs/Buchwert) | 2,28 |
| KUV (Kurs/Umsatz) | 4.793 |
| Eigenkapitalrendite | - |
| Eigenkapitalquote | +90,47% |
| Handelsplatz | Letzter | Änderung | Vortag | Zeit | |
|---|---|---|---|---|---|
| Düsseldorf | 23,97 € | -1,60% | 24,36 € | 27.02.26 | |
| Frankfurt | 24,48 € | +0,49% | 24,36 € | 27.02.26 | |
| Stuttgart | 24,72 € | +7,71% | 22,95 € | 27.02.26 | |
| L&S RT | 24,58 € | -1,23% | 24,885 € | 13:02 | |
| NYSE | 29,33 $ | -0,61% | 29,51 $ | 27.02.26 | |
| Nasdaq | 29,43 $ | -0,24% | 29,50 $ | 27.02.26 | |
| AMEX | 28,54 $ | +0,56% | 28,38 $ | 27.02.26 | |
| Tradegate | 25,25 € | +0,96% | 25,01 € | 27.02.26 | |
| Quotrix | 24,83 € | +1,60% | 24,44 € | 27.02.26 | |
| Gettex | 24,57 € | -0,53% | 24,70 € | 27.02.26 | |
| Datum | Kurs | Volumen |
|---|---|---|
| 27.02.26 | 29,37 | 103 T |
| 26.02.26 | 29,50 | 113 T |
| 25.02.26 | 28,82 | 85 T |
| 24.02.26 | 29,40 | 270 T |
| 23.02.26 | 28,09 | 124 T |
| Zeitraum | Kurs | % |
|---|---|---|
| 1 Woche | 27,47 $ | +6,77% |
| 1 Monat | 33,53 $ | -12,53% |
| 6 Monate | 18,55 $ | +58,11% |
| 1 Jahr | 15,32 $ | +91,45% |
| 5 Jahre | 16,70 $ | +75,63% |
| Marktkapitalisierung | 1,42 Mrd. € |
| Aktienanzahl | 52,59 Mio. |
| Währung | EUR |
| Land | USA |
| Sektor | Gesundheit |
| Branche | Biotechnologie |
| Aktientyp | Stammaktie |
| +14,99% | FMR Inc |
| +6,76% | BlackRock Inc |
| +6,59% | Deep Track Capital, LP |
| +5,97% | COMMODORE CAPITAL LP |
| +5,52% | Vanguard Group Inc |
| +5,42% | Kynam Capital Management, LP |
| +4,75% | VR Adviser, LLC |
| +4,24% | Fairmount Funds Management LLC |
| +3,55% | T. Rowe Price Associates, Inc. |
| +3,48% | TANG CAPITAL MANAGEMENT LLC |
| +3,36% | Paradigm Biocapital Advisors LP |
| +3,13% | State Street Corp |
| +2,91% | Novo A/S |
| +2,76% | Maverick Capital Ltd |
| +2,38% | AllianceBernstein L.P. |
| +2,33% | Eversept Partners, LLC |
| +2,14% | Baker Bros Advisors LP |
| +2,13% | Geode Capital Management, LLC |
| +1,64% | Loomis, Sayles & Company LP |
| +1,59% | Parkman Healthcare Partners LLC |
| +14,36% | Weitere |
| 0,00% | Streubesitz |
Zahlen für Q1/21
Company believes that its current cash, cash equivalents and short-term investments will be sufficient to fund its operations into 2024
VRDN-001 and VRDN-002 programs for Thyroid Eye Disease (TED) progressing; on track for IND filings in fourth quarter of 2021
http://investors.miragen.com/press-releases/press-release/2021/Viridian-Therapeutics-Reports-First-Quarter-2021-Financial-Results-and-Provides-Corporate-Updates/default.aspx
